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Summary
Background Actinic keratoses (AKs) are common premalignant skin lesions trig-
gered by excessive ultraviolet exposure. The majority of AKs regress or persist,
but some progress to squamous cell carcinomas. Biomarkers associated with their
persistence, progression and regression have not been characterized.
Objectives We performed skin biopsies in patients with extensive actinic damage to
identify biomarkers that correlate with clinical progression and regression of AKs.
Methods This was an observational study of a cohort of patients with extensive
actinic damage. AKs were mapped on a clear plastic template in 26 patients at
months 3, 6, 9 and 11. Biopsies were taken from randomly selected, predeter-
mined AKs and were evaluated for p53, E-cadherin, Snail, Slug and Twist. The
study is registered at Clinicaltrials.gov: NCT00027976.
Results p53 exhibited greater expression in clinically apparent AKs (histological
score 289  145) than in regressed AKs (075  096); P < 001. There was also
significantly less membrane E-cadherin, the lack of which is a marker of epithe-
lial–mesenchymal transition, in clinically apparent AKs (189  181) than in
sun-exposed skin (307  175); P < 0005. The E-cadherin transcription repres-
sors Snail, Slug and Twist were increased in AKs compared with sun-exposed skin.
A limitation of the study is that measurement of histological biomarkers was not a
primary end point. In addition, patients were allowed to apply sunscreens.
Conclusions At the molecular level, loss of E-cadherin and an increase in p53 are
linked to the dynamic interplay between the persistence, progression and regres-
sion of AKs.
What’s already known about this topic?
• Actinic keratoses (AKs) are common dysplastic epidermal lesions that result from
chronic and excessive ultraviolet exposure.
• Biomarkers associated with progression and regression of AK have not been charac-
terized.
What does this study add?
• Decreased E-cadherin and increased p53, Snail, Slug and Twist (E-cadherin tran-
scription factors) were associated with progression from AK to nonmelanoma skin
cancer.
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What is the translational message?
• Strategies targeting these molecules may be effective in reversing rising skin cancer
rates.
• E-cadherin, p53, Snail, Slug and Twist are potential biomarkers that may be used
to assess the efficacy of existing chemopreventive agents.
Actinic keratoses (AKs), also known as solar keratoses, are
common dysplastic epidermal lesions that result from chronic
and excessive ultraviolet (UV) exposure. Clinically, they range
from small, flesh-coloured, erythematous papules to large pla-
ques with yellow or brown scales and crusts that appear on
sun-exposed areas of the face, scalp and extremities.1,2 In indi-
viduals with multiple AKs, the cumulative lifetime risk of
developing an invasive squamous cell skin cancer is as high as
6–10%.3 Histologically, AKs are composed of atypical ker-
atinocytes characterized by alternating areas of parakeratosis
and orthokeratosis, a loss of polarity, pleomorphic or hyper-
chromatic nuclei and an inflammatory infiltrate comprised of
lymphocytes or plasma cells.
AKs are more frequent in individuals over the age of 45
years, due to escalating photodamage from cumulative sun
exposure.4,5 Other risk factors include lower Fitzpatrick sun
reactive skin types, residence in lower latitudes, male sex,
baldness, a prior history of skin cancer and an immunocom-
promised state.4,6–8 Management of actinically damaged skin
represents a considerable burden to the healthcare systems of
many countries worldwide.5 Based on U.S. health claims data,
estimates are that over 10 million individuals in the U.S.A. are
evaluated and treated annually for actinically damaged skin, at
a cost of U.S. $168 billion.5
The p53 tumour suppressor gene controls cell proliferation,
regulates apoptosis and facilitates DNA repair by interrupting
cell-cycle progression. p53 mutations are the most common
genetic alteration associated with the development of various
types of cancers including squamous cell carcinoma
(SCCs).9,10 Chromosomal p53 mutations are present in 90%
of SCCs and up to 100% of AKs.9
E-cadherin is an intercellular adhesion molecule that plays a
significant role in maintaining epithelial architectural integrity.
E-cadherin repression permits nonmotile epithelial cells to
transform into motile mesenchymal-like cells through a pro-
cess known as epithelial–mesenchymal transition.11,12 The
resulting cellular phenotype is characterized by loss of inter-
cellular bonds and an increase in migrational ability, leading
to tumour invasion.13 E-cadherin expression is a highly regu-
lated process, and the E-cadherin transcription repressors Snail,
Slug and Twist play an important regulatory role in epithelial–
mesenchymal transition.14
The purpose of this study was to investigate the natural his-
tory of AKs in patients with extensive actinic damage and to
determine whether biomarkers might predict which AKs are
likely to progress to keratinocyte cancers (KCs) and which are
likely to regress back to non-AK-bearing, sun-exposed skin. KCs
are also known as nonmelanoma skin cancers (NMSCs), and the
two terms are used interchangeably in this manuscript.
Materials and methods
Actinic keratosis mapping
This was an observational study of a cohort of patients with
extensive actinic damage. We used data and biopsy specimens
collected from 26 participants in the celecoxib NMSC chemo-
prevention trial who were randomized to receive placebo.15
Only samples from patients on placebo were included in the
study. Approval for the study was obtained prior to its initiation
from the University of Alabama at Birmingham (UAB) institu-
tional review board. Individuals at high risk for NMSC were eli-
gible to participate if they were over 18 years of age, had an
extensive number of AKs and had Fitzpatrick skin types I, II or
III. To be qualified as high risk, patients were required to have
10–40 AKs on the upper extremities, neck, face and scalp along
with prior histological evidence of at least one AK or NMSC.15
Participants were instructed to abstain from topical prescrip-
tion and over-the-counter medications; however, moisturizers,
emollients and sunscreens were allowed. The patients were
evaluated for AKs at 0, 3, 6, 9 and 11 months. A study inves-
tigator marked the location of each AK on a clear plastic tem-
plate that was placed over the upper extremities, neck, face
and scalp. Lesions with characteristic scaling, keratotic patches,
erythema and sandpaper-like scale were identified as AKs.15
The study investigators used different plastic templates to mark
AKs at each visit and were blinded to the template results
from previous visits. At the end of the study, AK templates
from months 0, 3, 6, 9 and 11 were compared to assess the
number of new, persistent and regressed AKs.
Skin biopsies and histological grading
At baseline, two AKs on the upper extremities were randomly
selected for biopsy, one of which was removed at baseline and the
other at month 9. If, at month 9, an AK selected for biopsy was no
longer present clinically, the site at which it had been located (i.e.
regressed AK) was still biopsied. AK biopsies were evaluated based
on the degree of proliferation and severity of atypia.
Each component in this grading scheme was given a score
of 1–3 (Table 1). Nodular basal cell carcinoma (BCC) and
well-differentiated SCC samples were obtained from the UAB
tissue bank and were not from the patients who had been fol-
lowed for 11 months.
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Biomarker expression
Biomarker expression was graded based on staining intensity and
the continuity of expression. For p53, Snail, Slug and Twist this
was 0, no staining; 1, minimal; 2, mild; 3, moderate; 4, strong;
5, very strong; and for E-cadherin: 0, no staining; 1–2 minimal;
3–4, mild; 5–6, moderate; 7–8, strong; 9–10, very strong.
Immunofluorescence staining
Paraffin tissue sections after deparaffinization and rehydration
were processed further for immunofluorescence staining. Non-
specific antibody binding was blocked with 2% bovine serum
albumin. After overnight incubation with primary antibodies
to E-cadherin and p53 (Santa Cruz Biotechnology, Dallas, TX,
U.S.A.), the tissue sections were incubated with a fluores-
cence-coupled secondary antibody and visualized using fluo-
rescence microscopy.
Immunohistochemical staining
The paraffin-embedded tissue sections were deparaffinized and
rehydrated. The antigen unmasking was done with 10 mmol
L1 citrate buffer (pH 60) and the nonspecific antigen bind-
ing was blocked by incubation with 2% bovine serum albu-
min. The sections were incubated overnight at 4 °C with
primary antibodies to Snail, Slug and Twist (Santa Cruz
Biotechnology). This was followed by incubation with peroxi-
dase-coupled secondary antibody and, finally, visualization
with 3,30-diaminobenzidine substrate.
Statistical analysis
The primary objective of this analysis was to assess whether
there are biomarkers that can correlate with progression to
skin cancer. The secondary objective was to determine the nat-
ural history of AKs. An independent Student’s t-test was con-
ducted to compare biomarker expression grading scores
among the various tissue sample groups.
Results
Twenty-six white patients with extensive actinic damage on
the upper extremities, neck, face and scalp were enrolled in
the study. Table 2 summarizes the patient characteristics. In
total 610 AKs were present at baseline, with a mean  SD of
235  79 AKs per person. The total number of lesions
remained steady over the 11-month observation period
(Table 3). At 11 months there was a mean increase of only
17  118 AKs per patient from baseline, which was not sta-
tistically significant. This is because over the 11 months, a
nearly equivalent number of new AKs appeared as regressed.
Overall, 43% clinically regressed without recurrence, while 87
(143%), 52 (85%), 42 (69%) and 82 (134%) regressed at
3, 6, 9 and 11 months, respectively. The mean time to regres-
sion was 62 months. On the other hand, 326% of AKs pre-
sent at baseline regressed and recurred at one of the follow-up
visits; 24% never regressed, 8% regressed twice and 1%
regressed twice and recurred twice.
Histological features of actinic keratoses
There were 18 pairs of biopsies evaluated at baseline and at 9
months, for a total of 36 biopsies. Of the 36 AKs clinically
present and biopsied, five were not confirmed as AKs based
on histological analysis (lichen simplex chronicus or solar
lentigines). Five of 18 of the 9-month biopsies had regressed
and did not show histological evidence of AK. There was not
a statistically significant change in the degree of proliferation
or atypia of the AKs over the 9-month period (Fig. 1).
Biomarker analysis
Because changes in mutant p53 and E-cadherin are associated
with SCC development in animal models,9,11,16 we sought to
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Table 3 Number of actinic keratoses (AKs) present on each patient
Timepoint AKs per patient, mean  SD Total no. of AKs
Baseline 235  79 610
Month 3 258  131 671
Month 6 231  116 600
Month 9 278  169 723
Month 11 250  166 650
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determine whether there was a change in p53 and/or E-cad-
herin expression when sun-protected skin, chronically sun-
damaged skin and AKs were compared. AKs and sun-exposed
skin both expressed p53. Significantly reduced p53 was
observed in regressed AKs and non-sun-exposed skin samples
compared with clinically apparent AKs and sun-exposed skin
(Fig. 2). BCC and SCC specimens were not collected from the
patients enrolled in the study. Therefore, representative
Fig 1. Histological score for the atypia and proliferation severity of randomly selected actinic keratoses (AKs) at baseline and when biopsied at 9
months. At baseline vs. month 9: P = 052 for proliferation, P = 044 for atypia and P = 037 for atypia and proliferation (both).
(a)
(b)
p53   
  DAPI     
B  D  F H 
NSE SE AK 
Regressed 
AK 
Fig 2. (a) Average nuclear expression score of p53 in skin biopsy samples: non-sun-exposed skin (NSE), sun-exposed skin (SE), clinically present
actinic keratosis (AK), regressed AK, basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and combined BCC and SCC (i.e. nonmelanoma
skin cancer, NMSC). (b) Immunofluorescence of p53 with 40,6-diamidino-2-phenylindole (DAPI). The arrows depict nuclear expression of p53.
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samples were taken from the UAB tissue bank of cutaneous
diseases. Those tissues showed enhanced expression of p53
relative to non-sun-exposed skin.
As E-cadherin is associated with progression of skin cancers
in animal models,11 sun-protected skin, chronically sun-
damaged skin, AKs and KCs were analysed for E-cadherin
expression. There was a progressive decline from non-sun-
exposed skin to sun-exposed skin to AKs (Fig. 3). E-cadherin
expression in BCC and SCC was similar to that in AKs, sug-
gesting at this point that it may be more of a marker of AK
persistence rather than progression to KCs. In sites in which
AKs had regressed, E-cadherin expression was less, although
not significantly, than in AKs that had not regressed (Fig. 3).
E-cadherin is carefully regulated by the transcription repres-
sors Snail, Slug and Twist.16 We investigated whether these
proteins might be altered in actinically damaged skin. Sun-
exposed skin, AK, BCC and SCC expressed significantly greater
levels of Snail, Slug and Twist than non-sun-exposed skin
(Fig. 4). In addition, expression levels of these proteins were
significantly reduced in regressed AK samples compared with
sun-exposed skin, AK and BCC (Fig. 4).
Discussion
AKs are common preneoplastic lesions that are precursors and
risk factors for cutaneous SCCs.1,6,7,17–20 Their prevention and
treatment reduce the significant likelihood of developing one
or more KCs.1 We found that the appearance and regression
of AKs is a dynamic process. The same AKs that were present
at one time were absent at another, but had the capacity to
reappear later. Over 40% of AKs identified at baseline
regressed over the 11-month observation period, 33%
recurred, 11% regressed twice and a small number reappeared
twice. As a result, the aggregate number of AKs over 11
months remained relatively constant. Moreover, there was no
change in the histological severity of the AKs biopsied at 9
(a)
(b)
Fig 3. (a) Average E-cadherin expression in skin biopsy samples. Non-sun-exposed skin (NSE), sun-exposed skin (SE), clinically present actinic
keratosis (AK), regressed AK, basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and combined BCC and SCC (i.e. nonmelanoma skin
cancer, NMSC). (b) Immunofluorescence of E-cadherin with 40,6-diamidino-2-phenylindole. Note that the cell membrane staining that outlines
the cells is greater in the NSE and SE than in the AK, regressed AK, BCC and SCC.
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months, suggesting that additional insults are required for
them to progress on to become SCCs. In this regard, treatment
with the cyclooxygenase-2 inhibitor celecoxib has been shown
to diminish the incidence of BCCs and SCCs, but has no effect
on AKs.15
The percentage of lesions that regressed in our analysis is
similar to that reported in some,21 but not all studies.22–26
This may be due to differences in the extent of actinic dam-
age, the experimental design, regional AK prevalence and/or
factors such as patients’ age, sex, sunscreen use and/or
amount of UV exposure.
There are multiple options for the treatment of AKs, includ-
ing, but not limited to, local (liquid nitrogen cryotherapy,
electrodesiccation and curettage) and field therapy (topical 5-
fluorouracil, imiquimod, diclofenac, ingenol mebutate and
photodynamic therapy).1 The concept that AKs can regress
and recur has important clinical implications for AK treatment
in individuals with extensive actinic damage. As only a minor-
ity of AKs are present at any one time, either field treatment
or repeated aggressive local treatment is necessary for adequate
management of these lesions. Based on the observation that
AKs can persist, progress or regress, another implication is that
it should be possible to intervene to promote regression and/
or retard progression of AKs.
A main goal of this study was to identify biomarkers that
are associated with progression and regression of AKs, in
order to develop pharmacological agents that might be
employed to inhibit the development of KC. Our analysis
found significantly increased p53 expression in AK, BCC, SCC
and sun-exposed samples compared with non-sun-exposed
(a)
(b)
NSE vs. SE NSE vs. AK NSE vs. Reg AK SE vs. Reg AK AK vs. Reg AK SE vs. AK
Snail P < 0·001 P < 0·001 P < 0·01 P < 0·001 P < 0·001 P > 0·05
Slug P < 0·001 P < 0·001 P < 0·01 P < 0·01 P < 0·01 P < 0·01
Twist P < 0·001 P < 0·001 P < 0·01 P > 0·05 P > 0·05 P > 0·05
TSIWTGULSLIANS
Fig 4. (a) Average group score of Snail, Slug and Twist expression in non-sun-exposed skin (NSE), sun-exposed skin (SE), clinically present
actinic keratosis (AK), regressed AK, basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and combined BCC and SCC (i.e. nonmelanoma
skin cancer, NMSC). (b) Histochemical staining for Snail, Slug and Twist.
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and regressed AKs. p53 alterations have been associated with
the early stages of UV-induced carcinogenesis both in animal
models and in human studies.9,27 Mutant p53 exhibits a
longer half-life than its wild-type counterpart and, as a
result, is likely to accumulate in the cell nucleus.28–30 We
observed that there was a progressive increase in nuclear p53
staining as the skin progressed from actinically damaged skin
to AK to KCs. p53 decreased in regressed AKs. These findings
suggest that p53 may be a good biomarker of AK progres-
sion. While it is uncertain whether AKs can progress to
BCCs, it is well established that people with large numbers
of AKs are at increased risk of developing BCCs.3 This associ-
ation is most likely due to the fact that extensive sun expo-
sure causes both.
Downregulation of E-cadherin expression, which leads to a
reduction in intercellular adhesion, has previously been linked
to AK and KC progression.31,32 In contrast to the increased
expression of p53 with more advanced premalignancies and
malignancies, there was a progressive decrease in E-cadherin
from non-sun-exposed skin to sun-exposed skin to AKs.
Although it was significantly less than in non-sun-exposed
skin, it is important to note that there was no further decline
in E-cadherin from AKs to NMSCs, implying that loss of E-
cadherin may be required for clinical progression of normal
skin to sun-damaged skin to AKs, but not for further progres-
sion to NMSCs.
Snail, Slug and Twist contribute to the downregulation of
E-cadherin and consequently have been connected to invasion
and metastasis of cancer cells.11,33 Various studies have sug-
gested that such transcriptional repressors are involved in KCs
as well,34–36 but none has examined the implications of Snail,
Slug and Twist in UV-exposed, AK and regressed AK samples.
There were higher levels of these proteins in UV-exposed skin
and in AKs than in control non-UV-exposed skin. The corre-
sponding reduction of E-cadherin in these samples suggests
that increased activity of these transcriptional regulators in AKs
and KCs contributes to the loss of E-cadherin and ultimately
to the progression of sun-exposed skin to UV-induced cuta-
neous tumours.
One limitation of our study was that biomarkers were not a
primary end point of the study. In addition, for ethical rea-
sons, all patients were allowed to use sunscreen, which may
itself alter the natural history of AKs.
An estimated 5 million new cases of NMSC will be treated
in the U.S.A. this year.37 While the mortality rate for most
NMSCs is not high, they can be locally destructive and their
treatment represents a tremendous economic impact on the
U.S. healthcare system and healthcare systems around the
world.5 Current methods for their prevention (AK treatment,
limiting sun and tanning bed exposure, sunscreens and other
photoprotective measures) have not been successful in stem-
ming the increasing incidence of these types of malignancy.
Thus, there has been great interest in identifying novel agents
for chemoprevention. By examining changes in the expression
of p53 and E-cadherin, the findings from this study can be
employed to determine the potential efficacy of existing and
novel measures for the prevention of NMSCs. Moreover, p53,
E-cadherin or one of the E-cadherin repressors could be used
as a biomarker to identify subsets of AKs that are at high risk
of progressing to SCCs. Our results also confirm that p53 and
E-cadherin are relevant targets for the prevention of skin can-
cer. In this regard, preclinical studies from our laboratory have
shown that CP-31398, a pharmacological agent that produces
conformational changes in mutant p53, enhancing its biologi-
cal activity, confers resistance to UV-induced cancer develop-
ment when applied topically.38 Additional therapeutic
strategies that enhance E-cadherin expression or lower mutant
p53 levels may be effective in reversing the rising incidence
of KC.
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